Opinion

Video

Cyclosporine Ophthalmic Solution for Inflammatory Dry Eye

Author(s):

Alice Epitropoulos, MD,Laura M. Periman, MD

Dry eye experts discuss Cyclosporine ophthalmic solution.

Video content above is prompted by the following question(s):

1. Cyclosporine ophthalmic solution, 0.1% (VEVYE)

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
Aldeyra Therapeutics hits primary end point in 1 of 2 phase 3 trials for reproxalap
May 7th 2025

Aldeyra Therapeutics hits primary end point in 1 of 2 phase 3 trials for reproxalap

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)
September 13th 2023

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)

Characteristics of dry eye disease in patients with autoimmune diseases
April 23rd 2025

Characteristics of dry eye disease in patients with autoimmune diseases

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)
September 13th 2023

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)

Harrow expands VEVYE Access for All program to Klarity-C patients
April 11th 2025

Harrow expands VEVYE Access for All program to Klarity-C patients

Nordic Pharma receives CE Mark for canalicular gel Lacrifill
April 7th 2025

Nordic Pharma receives CE Mark for canalicular gel Lacrifill

© 2025 MJH Life Sciences

All rights reserved.